No Benefit With Addition of EGFR Inhibitor to Chemotherapy in Esophageal Cancer
The addition of an EGFR inhibitor to a chemotherapy regimen did not improve outcomes when it came to cancers of the esophagus.
ESMO GI 2018
Eosinophil-to-Lymphocyte Ratio Associated with Shorter Survival in Pancreatic Cancer
Are systemic inflammatory biomarkers in the blood potential prognostic markers of overall survival in pancreatic cancer?
Risk of Brain Metastasis in Colorectal Cancer Dependent on Tumor Location and Other Metastatic Sites
In patients with colorectal cancer, rectal tumors and lung metastasis appeared to be linked to an elevated risk for brain cancer.
Capecitabine-Activating Enzyme Levels Prognostic for Metastatic Gastric Cancer Outcomes
XP-treated patients with metastatic gastric cancer who had tumors expressing UCK2 and OPRT above a specific threshold survived longer than patients with lower levels of these biomarkers.
Cetuximab/Irinotecan Rechallenge Active in Resistant Metastatic Colorectal Cancer
The CRICKET trial is evaluating the third-line retreatment of patients with mCRC with cetixumab plus irinotecan.
Increasing the Mutant Allele Fraction Cutoff in NGS Improved Mutation Detection in mCRC
Increasing the sensitivity cutoff from 5% to 1% in next-generation sequencing allowed for the identification of 28% more RAS/BRAF mutations.
First-Line Pancreatic Cancer Treatment Varies Across Europe, But Aligns With ESMO Guideline
The country-specific differences may be attributable to local reimbursement status.
Baseline Appetite Associated With Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma
A study reported post-hoc subgroup analyses of the international phase 3 NAPOLI-1 trial.
Liquid Biopsy Test Accurately Detects RAS Mutations in Metastatic Colorectal Cancer
The OncoBEAM RAS kit for circulating tumor DNA (ctDNA) analysis of patients with metastatic colorectal cancer (mCRC) demonstrated high positive and negative agreement of RAS mutations detected by tumor tissue analysis.
Better Quality of Life With Nab-Paclitaxel Added to Gemcitabine in Pancreatic Cancer
The combination of nab-paclitaxel plus gemcitabine improved quality of life scores and increased time to deterioration compared with gemcitabine monotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ESMO GI 2018
Loading... 
Loading...